The Next Big Thing in Brain and Pain Tech
What if we could read the brain with greater clarity—and treat pain without a scalpel?
NeuroOne Medical Technologies (NASDAQ: NMTC) is advancing that possibility. Its ultra-thin, high-resolution electrode technology is designed to interface with more neurons, unlocking new levels of precision for diagnosing and treating neurological conditions. Already FDA-cleared for use in epilepsy monitoring and brain mapping, NMTC’s electrodes are in clinical use at top academic hospitals in the U.S.
The same thin-film technology is also being developed for chronic pain, enabling a minimally invasive approach where a flexible electrode is inserted through a needle to target nerves in the spine—no incisions required.
Looking ahead, NMTC is exploring how this platform could support targeted drug delivery directly to specific brain regions—potentially enabling more precise delivery of cell and gene therapies, along with real-time monitoring of their effects. While still in development, this represents a promising frontier for future strategic partnerships.
This September, NMTC’s ablation platform will be featured at a leading pain conference, where Dr. Sean Li—an early clinical user—will present the technology and describe it as “The Next Big Thing” in neuromodulation.
NMTC vs. Neuralink: A Real Contender in the Neurotech Race
While Neuralink has captured headlines, NMTC is already commercially active. Neuralink is still awaiting FDA clearance, while NMTC has three FDA-cleared products in use at academic centers across the U.S.
With a fraction of the valuation—and actual revenue being generated—NMTC represents a unique opportunity in the neurotech space.
FDA-Approved and Commercially Deployed
This isn’t theoretical technology. NMTC currently has three FDA-cleared products, including the Evo® sEEG and cortical electrode systems, and its OneRF® system for ablation.
These tools are actively being used at some of the nation's top academic hospitals. In April 2025, NMTC submitted a 510(k) for a new indication: ablation of the trigeminal nerve to treat trigeminal neuralgia, a severe and often debilitating facial pain disorder.
Strategic Partnership with a $25 Billion Powerhouse
Since 2020, NMTC has been partnered with Zimmer Biomet—a global leader in surgical and musculoskeletal technology. Zimmer distributes NMTC’s Evo® diagnostic system for epilepsy. In 2025, the relationship expanded, including a $3 million upfront payment and supply agreement, reinforcing Zimmer’s long-term confidence in NMTC’s platform.
Big Moves on the Horizon
